Sign Up for Free!

Continue Analyzing the page and more.

Continue with Google

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Upgrade to Pro
Home Daily Intelligence Tracker
    • Plans Blog Contact
    Alterity Therapeutics Ltd logo
    ATHE

    Alterity Therapeutics Ltd

    MaveScore 17 Low model confidence
    Last Price US$4.41 As of Jun 15, 2026
    Market Cap US$37.8b Company size context
    7D Performance 13.08% Past 7 days
    1Y Performance 8.80% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Updating

    Refreshing

    Market price date

    Jun 15, 2026

    1 day old

    Coverage

    10/16

    6 missing model inputs

    Data quality

    Review

    Partial or delayed snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 17 Low confidence

    Stored data quality

    Freshness and coverage checks

    Stored company inputs are available, but some dates or model fields are older or incomplete.

    10/16 Partial or delayed snapshot

    Quality

    Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

    2/35 Weak

    Financial Strength

    Financial strength needs live profitability and cash-flow fields.

    0/25 Needs Data

    Valuation Support

    Valuation needs price plus per-share earnings, cash-flow, or book-value inputs.

    0/15 Needs Data

    Momentum

    Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

    13/15 Strong

    Shareholder Alignment

    Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

    2/10 Weak

    Positive model output

    • Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

    Research risks to review

    • Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.
    • Financial strength needs live profitability and cash-flow fields.
    • Valuation needs price plus per-share earnings, cash-flow, or book-value inputs.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting. Missing inputs right now include return on equity, net margin, gross margin, free cash flow per share, book value per share, earnings per share.

    Overview Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Ratio
    Dashboard Funda..tals Deep..lue Prediction Screener Map

    Alterity Therapeutics Ltd Overview

    Industry: Biotechnology

    Sector: Healthcare

    Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

    Alterity Therapeutics Ltd is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

    Score

    Price History & Performance

    Review Alterity Therapeutics Ltd in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

    Recent News



    News Image
    Applying Wyckoff theory to Enigmatig Limited stock - Free Chart Alert System With Entry Targets
    2 minutes ago
    News Image
    Why ATHE stock is on top investor watchlists - Earnings Impact and Stock Reaction Analysis
    2 hours ago
    News Image
    Sectors Driving Future Growth for ATHE Stock - Swing Entry Insight With Forecast Accuracy
    2 hours ago

    Alterity Therapeutics Ltd Competitors

    Alterity Therapeutics Ltd operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

    Earnings Per Share

    EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

    Continue the analysis

    Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

    View plans
    Ticker Image

    Alterity Therapeutics Ltd

    US$4.41

    US$37.8b

    13.08%

    8.80%